Javascript must be enabled to continue!
Antigen evolution from D614, to G614, to Delta, and to Omicron subtype of SARS-CoV-2
View through CrossRef
Abstract
Importance: Since 2019, the antigens from Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) are keeping in evolution from initial D614, to G614, to Delta, and to Omicron. The reasons of why the D614 subtype of SARS-CoV-2 was mutated to G614 first, to Delta second, and to Omicron third, are very importance in public health.Objective: To determine if the “roughness” of the antigens is difference among the candidates leading to mutated to G614, Delta, and Omicron sub-type of SARS-CoV-2. The hypothesis is that, the “roughest” antigen mutated first, the least “rough” antigen mutated last.Design: Survey the amino acids sequence of SARS-CoV-2 in 2022.Setting: Data from NCBI.Participants: One D614 protein sequence and 3 G614 sequences were selected from NCBI data base. Seven peptides from SARS-CoV-2 were analyzed. Our findings suggest that the order of the evolution of antigens were from D614G, that we refer to as “rough” status, to Delta, which we refer to as “precise” status, and to Omicron, that we refer to as the “most precise” status. In this paper, we would like to show initial data of how the antigens from the initial D614 strain evolved to G614, to Delta, then to the Omicron variant of SARS-CoV-2. This finding could help with the development of reagents for detecting both D614G, Delta, and Omicron antigens, or even to help with the development of vaccines against mutated SARS-CoV-2 or to help to control covid-19 pandemic. Antigen for the D614G, Delta, and Omicron variants of SARS-CoV-2 can be designed in silicon, developed in a laboratory, and then confirmed in animal models.
Title: Antigen evolution from D614, to G614, to Delta, and to Omicron subtype of SARS-CoV-2
Description:
Abstract
Importance: Since 2019, the antigens from Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) are keeping in evolution from initial D614, to G614, to Delta, and to Omicron.
The reasons of why the D614 subtype of SARS-CoV-2 was mutated to G614 first, to Delta second, and to Omicron third, are very importance in public health.
Objective: To determine if the “roughness” of the antigens is difference among the candidates leading to mutated to G614, Delta, and Omicron sub-type of SARS-CoV-2.
The hypothesis is that, the “roughest” antigen mutated first, the least “rough” antigen mutated last.
Design: Survey the amino acids sequence of SARS-CoV-2 in 2022.
Setting: Data from NCBI.
Participants: One D614 protein sequence and 3 G614 sequences were selected from NCBI data base.
Seven peptides from SARS-CoV-2 were analyzed.
Our findings suggest that the order of the evolution of antigens were from D614G, that we refer to as “rough” status, to Delta, which we refer to as “precise” status, and to Omicron, that we refer to as the “most precise” status.
In this paper, we would like to show initial data of how the antigens from the initial D614 strain evolved to G614, to Delta, then to the Omicron variant of SARS-CoV-2.
This finding could help with the development of reagents for detecting both D614G, Delta, and Omicron antigens, or even to help with the development of vaccines against mutated SARS-CoV-2 or to help to control covid-19 pandemic.
Antigen for the D614G, Delta, and Omicron variants of SARS-CoV-2 can be designed in silicon, developed in a laboratory, and then confirmed in animal models.
Related Results
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
<span style="font-size: 11pt; color: black; font-family: 'Times New Roman','serif'">ΠΗΛΙΝΑ ΙΓ&Delta...
Un manoscritto equivocato del copista santo Theophilos († 1548)
Un manoscritto equivocato del copista santo Theophilos († 1548)
<p><font size="3"><span class="A1"><span style="font-family: 'Times New Roman','serif'">ΕΝΑ ΛΑΝ&...
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020
Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020
Introduction
The SARS-CoV-2 lineages carrying the amino acid change D614G have become the dominant variants in the global COVID-19 pandemic. By June 2021, all t...
Analyses of the Spike Proteins of Severe Acute Respiratory Syndrome-Related Coronaviruses
Analyses of the Spike Proteins of Severe Acute Respiratory Syndrome-Related Coronaviruses
Aim: To analyze spike proteins of Severe Acute Respiratory Syndrome (SARS)-related coronaviruses (CoVs) for their conserved motifs, Receptor-Binding Domain (RBD), Receptor Binding...
Virulence and infectivity were associated with different fragments in the Delta subtype of SARS-CoV-2
Virulence and infectivity were associated with different fragments in the Delta subtype of SARS-CoV-2
Since 2019, the antigens from Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) have evolved from the initial D614 wild strain in the first epidemic wave, to D614G muta...
Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests
Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests
Abstract
Background
SARS-CoV-2 serology tests are clinically useful to document a prior SARS-CoV-2 infection in patients with n...

